Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/PPLPHARMA stock hub

NSE/PPLPHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/PPLPHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

238.8B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/PPLPHARMA

In the news

Latest news · NSE/PPLPHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E130.1

P25 24.9P50 32.4P75 45.7

Trailing P/En/a

P25 24.8P50 35.9P75 56.9

ROE-4

P25 6.3P50 13.6P75 18.1

ROIC0.7

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/PPLPHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

INR

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	5,476
Employees Change	-1,243%
Employees Change Percent	-18.5
Enterprise value	INR 282B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE0DK501011
Last refreshed	2026-05-10
Market cap	INR 238.8B
Price	INR 179
Price currency	INR
Rev Per Employee	16,196,274.65x
Sector	Healthcare
Sic	2834
Symbol	nse/PPLPHARMA
Website	https://www.piramalpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.36%
EV Earnings	-86.52x
EV/EBIT	191.09x
EV/EBITDA	28.81x
EV/FCF	36.98x
EV/Sales	3.18x
FCF yield	3.19%
Forward P/E	130.08x
P/B ratio	2.93x
P/S ratio	2.69x
PEG ratio	1.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	1.02%
EBITDA Margin	9.86%
FCF margin	8.6%
Gross margin	63.49%
Gross Profit	INR 56.3B
Gross Profit Growth	0.62%
Gross Profit Growth Q	14.94%
Gross Profit Growth3 Y	11.06%
Net Income	INR -3.3B
Net Income Growth Years	0%
Pretax Margin	-1.99%
Profit Margin	-3.68%
Profit Per Employee	INR -595,215
ROA	0.34
Roa5y	1.51
ROCE	0.68
ROE	-4
Roe5y	0.14
ROIC	0.73
Roic5y	1.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-15.96%
Cagr3y	37.15%
EPS Growth Years	0
FCF Growth	234.58%
OCF Growth	85.21%
OCF Growth3 Y	50.59%
Revenue Growth	-3.08x
Revenue Growth Q	-0.08x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	7.79x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	INR 0.53
Assets	INR 179.7B
Cash	INR 13.6B
Current Assets	INR 71.9B
Current Liabilities	INR 47.6B
Debt	INR 56.7B
Debt EBITDA	INR 6.16
Debt Equity	INR 0.7
Debt FCF	INR 7.44
Equity	INR 81.6B
Interest Coverage	0.27
Liabilities	INR 98B
Long Term Assets	INR 107.7B
Long Term Liabilities	INR 50.4B
Net Cash	INR -43.2B
Net Cash By Market Cap	INR -18.09
Net Debt EBITDA	INR 4.94
Net Debt Equity	INR 0.53
Net Debt FCF	INR 5.66
Tangible Book Value	INR 40.2B
Tangible Book Value Per Share	INR 31.91
WACC	5.98

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.51
Inventory Turnover	1.2
Net Working Capital	INR 23.2B
Quick ratio	0.74
Working Capital	INR 24.3B
Working Capital Turnover	INR 3.97

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.43%
Dividend Growth	0%
Dividend Growth Years	2%
Dividend per share	INR 0.14
Dividend Years	2
Dividend Yield	0.08%
Ex Div Date	2025-07-16
Last Dividend	INR 0.14
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-15.95%
200-day SMA	177.2
3Y total return	158.05%
50-day SMA	151.7
50-day SMA vs 200-day SMA	50under200
All Time High	307.9
All Time High Change	-41.72%
All Time High Date	2024-11-06
All Time Low	63.1
All Time Low Change	184.37%
All Time Low Date	2023-03-28
ATR	7.77
Beta	0.37
Beta1y	0.88
Beta2y	0.48
Ch YTD	4.2
High	185.5
High52	226
High52 Date	2025-05-15
High52ch	-20.6%
Low	178.3
Low52	132.3
Low52 Date	2026-03-23
Low52ch	35.63%
Ma50ch	18.31%
Price vs 200-day SMA	1.26%
RSI	70.72
RSI Monthly	49.93
RSI Weekly	57.29
Sharpe ratio	-0.46x
Sortino ratio	-0.5
Total Return	0.51%
Tr YTD	4.2
Tr1m	27.23%
Tr1w	11.94%
Tr3m	13.03%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 903.8M
Operating Income Growth	-85.72
Operating Income Growth Q	-24.92
Operating margin	1.02

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	611,348,219%
Net Borrowing	2,829,600,000
Shares Insiders	0.19%
Shares Institutions	24.13%
Shares Out	1,327,850,780
Shares Qo Q	-4.71%
Shares Yo Y	-0.43%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	INR 7.2B
Average Volume	9,041,252.5x
Bv Per Share	64.78
CAPEX	INR -8.9B
Ch1m	27.23
Ch1w	11.94
Ch1y	-16.01
Ch3m	13.03
Ch3y	151.7
Ch6m	-9.9
Change	-2.33%
Change From Open	-2.21
Close	183.7
Days Gap	-0.13
Depreciation Amortization	7,844,600,000
Dollar Volume	1,108,180,707.1
Earnings Date	2026-04-28
EBIT	INR 903.8M
EBITDA	INR 8.7B
EPS	INR -2.46
F Score	4
FCF	INR 7.6B
FCF EV Yield	2.7x
FCF Per Share	INR 5.74
Financing CF	-389,800,000
Fiscal Year End	March
Founded	2,020
Goodwill	12,574,300,000
Income Tax	INR 1.5B
Investing CF	-8,260,300,000
Is Primary Listing	1
Last Earnings Date	2026-04-28
Last Report Date	2026-03-31
Ma150	170.3
Ma150ch	5.35%
Ma20	158.4
Ma20ch	13.31%
Net CF	7,939,400,000
Next Earnings Date	2026-05-14
Open	183.5
P FCF Ratio	31.32
P OCF Ratio	14.45
Payment Date	2025-08-29
Position In Range	15.9
Ppne	56,418,500,000
Price Date	2026-05-08
Price EBITDA	INR 27.3
Ptbv Ratio	5.94
Relative Volume	0.69x
Revenue	88,690,800,000x
SBC By Revenue	0.47x
Share Based Comp	417,200,000
Tax By Revenue	1.69x
Tr6m	-9.9%
Volume	6,175,773

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/PPLPHARMA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.1%

$0.14 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

2 consecutive years of growth

Total shareholder yield

+0.5%

Next ex-dividend date: 2025-07-16

Performance

NSE/PPLPHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/PPLPHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+24.1%

Share of float held by funds and institutions

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.4%

Negative means the company is buying back shares.

Technical

NSE/PPLPHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.7

Above 70: short-term overbought

Price vs 200-day MA

+1.3%

50/200-day relationship not available

Beta (5Y)

0.37

Less volatile than the market

Sharpe ratio

-0.46

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/PPLPHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/PPLPHARMA stock rating?

nse/PPLPHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/PPLPHARMA analysis?

The full report lives at /stocks/nse/PPLPHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/PPLPHARMA?

The latest report frames nse/PPLPHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/PPLPHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.